Company No:
Contents
| DIRECTORS | Carolyn Dawson |
| Tim Groot | |
| Cillian Mark Hilliard (Appointed 06 September 2024) | |
| Arnaud Jacques Michel Massenet | |
| Jeremy Byron Roche | |
| Hillel Louis Zidel (Resigned 06 September 2024) |
| REGISTERED OFFICE | Treviot House |
| 186-192 High Road | |
| Ilford | |
| IG1 1LR | |
| United Kingdom |
| COMPANY NUMBER | 09343609 (England and Wales) |
| ACCOUNTANT | Gravita Essex Limited |
| Treviot House | |
| 186-192 High Road | |
| Ilford | |
| Essex | |
| IG1 1LR | |
| United Kingdom |
| Note | 2024 | 2023 | ||
| £ | £ | |||
| Restated - note 2 | ||||
| Fixed assets | ||||
| Intangible assets | 5 |
|
|
|
| Tangible assets | 6 |
|
|
|
| Investments | 7 |
|
|
|
| 2,176,575 | 402,032 | |||
| Current assets | ||||
| Debtors | 8 |
|
|
|
| Cash at bank and in hand |
|
|
||
| 2,452,199 | 2,858,118 | |||
| Creditors: amounts falling due within one year | 9 | (
|
(
|
|
| Net current assets | 869,187 | 1,666,365 | ||
| Total assets less current liabilities | 3,045,762 | 2,068,397 | ||
| Net assets |
|
|
||
| Capital and reserves | ||||
| Called-up share capital |
|
|
||
| Share premium account |
|
|
||
| Other reserves |
|
|
||
| Profit and loss account | (
|
(
|
||
| Total shareholders' funds |
|
|
Directors' responsibilities:
The financial statements of Intros.At Limited (registered number:
|
Tim Groot
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.
Intros.At Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Treviot House, 186-192 High Road, Ilford, IG1 1LR, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.
Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.
Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Profit and Loss Account in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year.
Equity-settled share-based payment transactions are measured at fair value at the date of grant. The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Company’s estimate of shares that will eventually vest and adjusted for the effect of non-market-based vesting conditions.
Fair value is measured by use of the Black Scholes model which is considered by management to be the most appropriate method of valuation. The expected life used in the model has been adjusted, based on management’s best estimate, for the effects of non-transferability, exercise restrictions, and behavioural considerations.
Cancellations or settlements (including those resulting from employee redundancies) are treated as an acceleration of vesting and the amount that would have been recognised over the remaining vesting period is recognised immediately.
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.
| Other intangible assets |
|
| Plant and machinery etc. |
|
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis.
Fixed asset investments are measured at cost less impairment.
Expenditure on research and development is written off in the year in which it is incurred.
The company participates in an equity settled share-based payment arrangement in which share options are issued to employees of the group. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period. The fair value is calculated using the appropriate fair value model with the estimated level of vesting being reviewed annually by management. The key assumptions of this model are a risk-free rate of 0.1%-5.25%, a staff retention rate of 70% and that the fair value of the shares at grant date is equal to the amounts paid for the company's shares in the most recent round of investment to the grant date.
During the current financial year, the company identified errors in the recognition of deferred revenue and in the accounting treatment of equity-settled share-based payment transactions relating to share options granted to employees in prior periods. The company has restated the comparative figures to reflect the correct accounting treatment and the adjustment has been made retrospectively. The effect of the restatement on the prior year’s financial statements is summarised below:
| As previously reported | Adjustment | As restated | ||||
| Year ended 31 December 2023 | £ | £ | £ | |||
| Share option reserve | 2,872,574 | 198,832 | 3,071,406 | |||
| Investments | 0 | 28,357 | 28,357 | |||
| Deferred income | 931,536 | (21,650) | 909,886 | |||
| Retained earnings | (10,806,443) | (148,826) | (10,955,269) |
| 2024 | 2023 | ||
| Number | Number | ||
| Monthly average number of persons employed by the Company during the year, including directors |
|
|
Equity-settled share-based payment schemes
Details of the EMI share option schemes in issue as at 31 December 2024 are as follows:
17,696,976 share options were granted from 01/01/2016 to 31/12/2021 at an exercise price of £0.0001
1,409,000 share options were granted from 22/12/2020 to 31/12/2021 at an exercise price of £0.1977
950,000 share options were grantedon 01/03/2022 at an exercise price of £0.1977
1,825,000 share options were granted from 01/10/2023 to 31/12/2023 at an exercise price of £0.1977
600,000 share options were granted from 01/01/2024 to 31/12/2024 at an exercise price of £0.1977
Details of the share options outstanding during the financial year are as follows:
| 2024 | 2023 | ||||
|---|---|---|---|---|---|
| Weighted Average | Weighted Average | ||||
| Number of share options | Average exercise price (£) | Number of share options | Average exercise price (£) | ||
| Outstanding at beginning of period |
|
|
|
|
|
| Granted during the period |
|
|
|
|
|
| Forfeited during the period | (
|
|
(
|
|
|
| Exercised during the period | (
|
|
|
|
|
| Outstanding at the end of the period |
|
|
|
|
|
| Exercisable at the end of the period |
|
|
|
|
|
The Company recognised total expenses of £
| Other intangible assets | Total | ||
| £ | £ | ||
| Cost | |||
| At 01 January 2024 |
|
|
|
| Additions |
|
|
|
| At 31 December 2024 |
|
|
|
| Accumulated amortisation | |||
| At 01 January 2024 |
|
|
|
| Charge for the financial year |
|
|
|
| At 31 December 2024 |
|
|
|
| Net book value | |||
| At 31 December 2024 |
|
|
|
| At 31 December 2023 |
|
|
| Plant and machinery etc. | Total | ||
| £ | £ | ||
| Cost | |||
| At 01 January 2024 |
|
|
|
| Additions |
|
|
|
| At 31 December 2024 |
|
|
|
| Accumulated depreciation | |||
| At 01 January 2024 |
|
|
|
| Charge for the financial year |
|
|
|
| At 31 December 2024 |
|
|
|
| Net book value | |||
| At 31 December 2024 | 16,056 | 16,056 | |
| At 31 December 2023 | 0 | 0 |
Investments in subsidiaries
| 2024 | |
| £ | |
| Cost | |
| At 01 January 2024 |
|
| Additions |
|
| At 31 December 2024 |
|
| Carrying value at 31 December 2024 |
|
| Carrying value at 31 December 2023 |
|
| 2024 | 2023 | ||
| £ | £ | ||
| Trade debtors |
|
|
|
| Amounts owed by related parties |
|
|
|
| Other debtors |
|
|
|
|
|
|
| 2024 | 2023 | ||
| £ | £ | ||
| Trade creditors |
|
|
|
| Amounts owed to related parties |
|
|
|
| Other taxation and social security |
|
|
|
| Other creditors |
|
|
|
|
|
|
Commitments
| 2024 | 2023 | ||
| £ | £ | ||
| Total future minimum lease payments under non-cancellable operating leases |
|
|
Contingent assets